Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Authors

Garon EB; Sadeghi S; Kabbinavar FF; Reckamp KL; Marquez-Garban DC; Stabile LP; Goodglick L; Dubinett SM; Siegfried JM; Pietras RJ

Journal of Clinical Oncology, Vol. 26, No. 15_suppl, pp. 19091–19091

American Society of Clinical Oncology (ASCO)

May 20, 2008

10.1200/jco.2008.26.15_suppl.19091

0732-183X

Saman Sadeghi